{"name":"Immunocore Ltd","slug":"immunocore-ltd","ticker":"","exchange":"","domain":"immunocore.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Brenetafusp and pembrolizumab","genericName":"Brenetafusp and pembrolizumab","slug":"brenetafusp-and-pembrolizumab","indication":"Other","status":"phase_1"},{"name":"Brenetafusp and chemotherapy","genericName":"Brenetafusp and chemotherapy","slug":"brenetafusp-and-chemotherapy","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"Brenetafusp and pembrolizumab","genericName":"Brenetafusp and pembrolizumab","slug":"brenetafusp-and-pembrolizumab","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Brenetafusp and chemotherapy","genericName":"Brenetafusp and chemotherapy","slug":"brenetafusp-and-chemotherapy","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"Assessing Immunocore Holdings (IMCR) Valuation After Analyst Downgrade And Pipeline Timing Shift - simplywall.st","headline":"Assessing Immunocore Holdings (IMCR) Valuation After Analyst Downgrade And Pipeline Timing Shift","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxOSmgzZFc0S2xLUmZOYU9SZm5kODU4TV9wUDFJbXVrR00zWDBWWVVuV1pQNDduRVRxSkZJOXNWek5zeUt1dy1teVRGaVZubFZSajZmYl94N2pYbU9Cam4ycVhZNk9LZmRSejJiYTJkUC0ta0JGS3lyM0ctc01RX2RQS3hBa3Y5RkM5Zm4xN0VqajM0dnpLZDhRaXZIUXkyQ3A4UjhZcF9qdnVtRFRWLUt5OFJ2VVA1amRqdGdfdzBacEVwSklGNEd0NEo0aWZFdVllQnhES0ZaUGFxNkFJQ1BPSjF5UlZuVm84aG0yVkJOTmNDZDdOcE9lWGZOZkljejBZTjlTZFN5UzRmQjhOTDJUMHhHWUxlSUVVVHRnOXBua3VQUUlZcVVIeXpzRWpTcWM?oc=5","date":"2026-03-16","type":"pipeline","source":"24/7 Wall St.","summary":"Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More - 24/7 Wall St.","headline":"Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPTDcwc0YzQ0o1SDBocXhzbUFKMDdKQktrRmQyUXJ3d3RGV2Z4VURBbW02Z2ZhNlQ1dzRsXy1vTkJrWHZYMHBxWnljS21pVWdUQ0paT2dPQ19vQThKN1dZQnJLQXFRYlQ5OEhCalJKbWFyVkdLWmh2N0p3YUhhOUhZVHhBUHMwaFlJcWhHcnBGbDdHUmUtQWtrblEtRFM?oc=5","date":"2026-03-06","type":"trial","source":"openPR.com","summary":"TCR Therapy Clinical Trial Pipeline Accelerates as 50+ Pharma - openPR.com","headline":"TCR Therapy Clinical Trial Pipeline Accelerates as 50+ Pharma","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-28","type":"pipeline","source":"simplywall.st","summary":"Is It Time To Reassess Immunocore (IMCR) After Recent Biotech Progress And Valuation Signals - simplywall.st","headline":"Is It Time To Reassess Immunocore (IMCR) After Recent Biotech Progress And Valuation Signals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPNTRJWlI1ZHhzSnRKQnhuOXYtTjNNcXIxV2R3LWlNcjJvbjhnRmFJWXNCemhmV0taeDlEdlZWdlFwSV8xTXNCUF9wZ2VKZldTcDZmM0h6LU5yQ0dobnlSM0JjNTZod1JrdzFwR2lSZjlLWm9zNVMwM1licGN0RUhBMWROd0ltV3ptZU5neXBDYWlrUQ?oc=5","date":"2026-01-29","type":"earnings","source":"finviz.com","summary":"TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - finviz.com","headline":"TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQeWpuZlRhM1R5MjNTVFptZl9hTkdmY1M1V0NaMHJ0bGhmZnhiM2tsSzhoeDl5N0swaktBZ2k2NjlMSWZQem1jYVprelZnVVMzVEI4bURCQ3dhQWt6dlRodXNnYy1HT3RYTkk1TlR1ckR6eWU4VUJTTmttUUR0RnlYTktNOUFDUy1qOUJncktYcnFLSmRWbFZqSWs5UGV0WWVIWmZua0N1LUxJNEEyMW5n?oc=5","date":"2026-01-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"JPM26: Immunocore Signals Entry into type 1 diabetes - Pharmaceutical Technology","headline":"JPM26: Immunocore Signals Entry into type 1 diabetes","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxOcGR4djNIV0t1SW05Wm1nSlF3aVIxRUZDZ2NrNUFMSzNJdW5aUFZsbGdNb1RHSVdSWjZDVi1oNEtHM0xKMDlMZzFZbFNrSW4zSVFZeWowVGJpWmFCMUVzMEV0Z1hNNjNGaWRsMWMzcXgtaS1FeVA5QzllZXNqaWN3S1RyUERRWU5OVmx0SGprUTF6T1k?oc=5","date":"2025-07-29","type":"pipeline","source":"Yahoo Finance UK","summary":"Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More - Yahoo Finance UK","headline":"Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Li","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-13","type":"pipeline","source":"PR Newswire UK","summary":"The Galien Foundation Announces 2025 Prix Galien UK Award Candidates for \"Best Biotechnology Product,\" \"Best Digital Health Solution,\" \"Best Medical Technology,\" \"Best Pharmaceutical Product,\" \"Best P","headline":"The Galien Foundation Announces 2025 Prix Galien UK Award Candidates for \"Best Biotechnology Product,\" \"Best Digital Hea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZ0FVX3lxTFBmaFJwM2NpWFM0YkZKVkNrVzktRkZvYTJpVmF5cERNX1hxVjBJTXFsNU4wSG5uNFJLNmp6ZGt0ZGxDNWZ2WnlqVDNtYmRVZVphR3FuYlpyM1BKQnRXOWNJbTJiRXFjOG8?oc=5","date":"2025-02-06","type":"pipeline","source":"UnivDatos","summary":"Bispecific Antibody Market: Share, Size, Growth, Forecast to 2030 - UnivDatos","headline":"Bispecific Antibody Market: Share, Size, Growth, Forecast to 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOSjNOdm45YUNacFZPWGdRZFduZmZ0UXdfNDlUWUR5aEFxY1NHYldzRmk4RW1GTlhOaGVkZ3NYVDFsNlZ0SGk0TjFYWUhVaTloRUVSWDVabjBNWEluTHpzVVoyUHplb0ZOWmVOSEtFTXJuQWE0N2Q0MmtUTnk0WktCWXdXczlaU0dkREx5aVQtcXRCR0JsV3NBZjJPT01KUVU?oc=5","date":"2024-12-03","type":"pipeline","source":"PharmaTimes","summary":"KIMMTRAK recommended for funding by NICE for uveal melanoma patients - PharmaTimes","headline":"KIMMTRAK recommended for funding by NICE for uveal melanoma patients","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPUDlOSEktblRkMEtaaldIR3ktdzkxc21OaElWWTNITUI5bU1aM2FralNxeU1LT3RrYXk3YmVaWTd3V2lUeTVpQjF6ejk5UXJ5TDJFeEwteXFKd3BqSnhLekFUQzRjMkVPNTZnaEhiblN5eGQxLXdxUUlUanNSaWdIRWtkRk04TFh5bHhFN2NvQzFkSkJucFF1N2NEdHpzRTBOTkE?oc=5","date":"2024-04-22","type":"pipeline","source":"citybiz","summary":"ArriVent Appoints Kristine Peterson to its Board of Directors - citybiz","headline":"ArriVent Appoints Kristine Peterson to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPT3Nfd0ZQY3VCQTF2Umgwd3MydE5VNzVSR0d4NjlsSi1FMEI0QUJqTHpVSEZhNC1RaWVOR3FyMWpxdVZKNmtVRVVYaHNwR0drY0IxOHpCX1BfVGtGR2dlT3BBYXltRWZEQnBueXlXZjR2SkRENFFWM0xIVkVhYlNfYURNMms1YmlZcmc?oc=5","date":"2022-06-22","type":"deal","source":"labiotech.eu","summary":"Immunocore Boosts its Collaboration with GSK with new Lead Compound - labiotech.eu","headline":"Immunocore Boosts its Collaboration with GSK with new Lead Compound","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_1":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}